TVTX Stock: Price, Earnings History and SEC Filings
Travere Therapeutics, Inc. (TVTX) last traded at $50.39, down 0.36% on the latest session and down 14.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.37 against an analyst estimate of $-0.14, a miss of 164.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TVTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.37 | $-0.14 | -164.29% |
| Mar 2026 | May 4, 2026 | $-0.39 | $-0.30 | -30.00% |
| Dec 2025 | Feb 19, 2026 | $0.03 | $0.03 | +0.00% |
| Sep 2025 | Oct 30, 2025 | $0.28 | $-0.31 | +190.32% |
TVTX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How TVTX reacts to earnings
Across its last 8 earnings releases, TVTX moved 7.6% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | After close | +12.03% |
| 2026-05-04 | After close | -0.24% |
| 2026-02-19 | After close | +3.72% |
| 2026-01-12 | After close | -14.63% |
| 2025-10-30 | After close | +18.58% |
| 2025-08-06 | After close | -1.91% |
| 2025-02-20 | After close | -6.79% |
| 2025-01-13 | Before open | +2.76% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
TVTX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $491M | -$26M | – | -5.2% | $-0.29 |
| 2024 | $233M | -$322M | – | -137.9% | $-4.08 |
| 2023 | $145M | -$111M | -$281M | -76.7% | $-1.50 |
| 2022 | $109M | -$278M | -$186M | -254.4% | $-4.37 |
| 2021 | $132M | -$180M | -$20M | -136.6% | $-3.01 |
| 2020 | $198M | -$169M | -$50M | -85.4% | $-3.56 |
| 2019 | $175M | -$146M | -$58M | -83.5% | $-3.46 |
| 2018 | $164M | -$103M | -$26M | -62.5% | $-2.54 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for TVTX
- 8-K · Sep 21, 2026Officer or director change, Financial statements and exhibits
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 9, 2026Officer or director change
- 8-K · Jun 16, 2026Officer or director change
- 8-K · Jun 2, 2026Material agreement, Financial statements and exhibits
- 8-K · May 21, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 8-K · May 11, 2026Material agreement, New financial obligation, Unregistered share sale
- 424B5 · May 7, 2026
- 424B5 · May 5, 2026
Insider filing activity
TVTX insiders filed 11 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TVTX news
- Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue EstimatesOct 28, 2026 · finance.yahoo.com
- Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Oct 28, 2026 · finance.yahoo.com
- Travere Therapeutics to Report Third Quarter 2026 Financial ResultsOct 26, 2026 · finance.yahoo.com
- Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA NephropathyOct 23, 2026 · finance.yahoo.com
- AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA NephropathyOct 22, 2026 · finance.yahoo.com
- Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to DeclineOct 22, 2026 · finance.yahoo.com
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc. (TVTX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in CA. Its fiscal year ends in December.